MedXY AI/MedXY News/Section: Hematology-Oncology

Distinct Myeloid Landscapes Define Prognostic Niches in Extranodal NK/T-Cell Lymphoma

MedXY Editorial Team•Aug 27, 2026•Hematology-Oncology

Myeloid heterogeneity Tumor Microenvironment extranodal NK/T-cell lymphoma

Highlight

ENKTL exhibits two distinct myeloid-defined subgroups characterized by inflammatory or immune-quiescent macrophage programs.
An NF-κB-activated, EBV-associated tumor subset colocalizes with inflammatory macrophages, forming a prognostic inflammatory niche.
Tumor-myeloid cooperativity involves CCL- and IL1-mediated myeloid recruitment and self-reinforcement within the lymphoma microenvironment.
The abundance of this inflammatory niche correlates with improved survival, offering insights for targeted immunotherapeutic strategies.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Mapping the Tumor Microenvironment in Multiple Myeloma: Insights from Single-Cell Analysis Across Disease StagesThis study provides a comprehensive single-cell immune atlas of multiple myeloma, revealing dynamic tumor microenvironment ecotypes linked to disease progression, immune dysfunction, and treatment response, offering new avenues for precisioOct 16, 2026 Targeting the FGF18-FGFR3 Axis: A New Frontier in Acute Myeloid Leukemia TherapyFGF18 produced by stromal fibroblasts promotes AML progression via FGFR3-mediated AKT-mTOR signaling, forming a feed-forward loop that impairs CD8+ T-cell immunity. Neutralizing FGF18 synergizes with PD-1 blockade, suggesting a novel therapOct 9, 2026 Decoding CTCL: A Single-Cell Atlas Reveals Oncogenic Pathways and Immune Resistance MechanismsThis study presents a comprehensive single-cell RNA-sequencing atlas of CTCL, identifying oncogenic transcriptional programs and immune microenvironment features that offer new therapeutic targets for advanced-stage disease.Oct 8, 2026

Loading comments...

MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Work email address

Ask MedXY AI

Most popular

Intimate Health

Five Benefits for Women Continuing Sexual Activity After Menopause

Intimate Health

Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

How often should a couple have sex?

Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

General Surgery

Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

Targeting IGF2BP2: A Novel Therapeutic Avenue in Peripheral T-cell Lymphoma Through RNA Modification and Immune Modulation

This article explores the pivotal role of IGF2BP2, an N6-methyladenosine reader, in driving tumor growth and immune evasion in peripheral T-cell lymphoma, highlighting its potential as a dual-action therapeutic target.

Sep 24, 2026

Neurotensin Receptor 1: A Key Driver of Immune Exclusion and Poor Prognosis in Colorectal CancerHigh expression of neurotensin receptor 1 (NTSR1) defines an immune-cold colorectal cancer subtype linked to worse outcomes by creating mechanical and biological barriers that exclude T-cell infiltration, highlighting a novel immunotherapeuSep 23, 2026

Unveiling the Molecular Evolution from Primary Gastric Cancer to Peritoneal Metastases: Implications for Targeted Surgical OncologyThis study elucidates transcriptomic differences between primary gastric cancers and peritoneal metastases, revealing distinct tumor microenvironments and molecular pathways, highlighting potential targets for improved diagnosis and therapySep 5, 2026